L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 5.86 NOK 0.34% Market Closed
Market Cap: 300.5m NOK
Have any thoughts about
Lytix Biopharma AS?
Write Note

Wall Street
Price Targets

LYTIX Price Targets Summary
Lytix Biopharma AS

Wall Street analysts forecast LYTIX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LYTIX is 14.28 NOK with a low forecast of 14.14 NOK and a high forecast of 14.7 NOK.

Lowest
Price Target
14.14 NOK
141% Upside
Average
Price Target
14.28 NOK
144% Upside
Highest
Price Target
14.7 NOK
151% Upside
Lytix Biopharma AS Competitors:
Price Targets
KMDA
Kamada Ltd
116% Upside
096530
Seegene Inc
43% Upside
MNKD
MannKind Corp
56% Upside
TNGX
Tango Therapeutics Inc
263% Upside
AMGN
Amgen Inc
25% Upside
PRQR
ProQR Therapeutics NV
224% Upside
SIGHT
Gensight Biologics SA
38% Upside

Revenue
Forecast

Revenue Estimate
Lytix Biopharma AS

For the last 5 years the compound annual growth rate for Lytix Biopharma AS's revenue is 64%. The projected CAGR for the next 2 years is 423%.

64%
Past Growth
423%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Lytix Biopharma AS

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Lytix Biopharma AS

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LYTIX's stock price target?
Price Target
14.28 NOK

According to Wall Street analysts, the average 1-year price target for LYTIX is 14.28 NOK with a low forecast of 14.14 NOK and a high forecast of 14.7 NOK.

What is Lytix Biopharma AS's Revenue forecast?
Projected CAGR
423%

For the last 5 years the compound annual growth rate for Lytix Biopharma AS's revenue is 64%. The projected CAGR for the next 2 years is 423%.

Back to Top